Medicine and Dentistry
Hodgkin's Lymphoma
100%
Autologous Stem Cell Transplantation
81%
Rituximab
79%
Classical Hodgkin Lymphoma
73%
Non-Hodgkin Lymphoma
73%
Diffuse Large B-Cell Lymphoma
65%
Positron Emission Tomography
58%
CHOP
52%
Disease
50%
Drug Megadose
49%
Burkitt's Lymphoma
43%
Radiation Therapy
42%
Posttransplant Lymphoproliferative Disease
41%
Epstein Barr Virus
41%
Neoplasm
35%
Tumor Cell
34%
Human Leukocyte Antigen
31%
Sjoegren Syndrome
31%
Hazard Ratio
31%
Arm
29%
Central Nervous System
29%
Doxorubicin
28%
Overall Survival
27%
Cyclophosphamide
24%
MALT Lymphoma
23%
Prognostic Factor
23%
Lymphoma
23%
Autologous Bone Marrow Transplantation
23%
Oncology
23%
Progression Free Survival
22%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
Immune Checkpoint Inhibitor
20%
Waldenström's Macroglobulinemia
20%
Granulocyte Colony Stimulating Factor
20%
B-Cell Lymphoma
20%
Reed-Sternberg Cell
20%
Acute Myeloid Leukemia
20%
Event Free Survival
20%
Etoposide
19%
Cytarabine
17%
Methotrexate
17%
B Cell
16%
Vincristine
16%
Progressive Disease
16%
Fluorodeoxyglucose F 18
15%
Side Effect
14%
Disease Specific Survival
14%
Testis Cancer
14%
Disease Free Survival
14%
Bleomycin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
90%
Chemotherapy
83%
Hodgkin Disease
63%
Remission
63%
Classical Hodgkin Lymphoma
62%
Disease
61%
Neoplasm
56%
Diffuse Large B Cell Lymphoma
56%
Burkitt's Lymphoma
41%
Alemtuzumab
41%
Cyclophosphamide
39%
Overall Survival
39%
Doxorubicin
38%
Nonhodgkin Lymphoma
36%
Malignant Neoplasm
35%
Peripheral T Cell Lymphoma
31%
Thymus and Activation Regulated Chemokine
31%
Progression Free Survival
30%
Epstein-Barr Virus
29%
Side Effect
27%
Methotrexate
26%
Prednisone
25%
Etoposide
22%
Primary Central Nervous System Lymphoma
20%
Sjoegren Syndrome
20%
Event Free Survival
18%
Failure Free Survival
16%
Cytarabine
16%
Bleomycin
15%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Vincristine
14%
Disease Free Survival
14%
Intrathecal
14%
Marginal Zone Lymphoma
13%
Infection
13%
Adverse Outcome
13%
Vinblastine
13%
Dacarbazine
13%
Lymphoma
13%
Monotherapy
12%
Tolerability
12%
Disease Course
12%
Digestive System Cancer
12%
Fluorodeoxyglucose F 18
11%
Phase II Trials
11%
Biological Marker
11%
Immunoglobulin G
11%
Vincristine Sulfate
11%
Clinical Trial
11%
Interleukin 3
10%
Keyphrases
Aggressive non-Hodgkin Lymphoma
41%
Classical Hodgkin Lymphoma
41%
Lymphoma Patients
37%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
36%
Poor Risk
31%
High Dose
26%
Dutch
25%
Belgian
23%
Oncohematology
23%
Overall Survival
22%
CHOP Chemotherapy
21%
Transplantation
21%
Post-transplant Lymphoproliferative Disorder
20%
Burkitt Lymphoma
20%
Allogeneic Bone Marrow Transplantation
20%
Slow Response
20%
Marrow Transplantation
20%
Cooperative Group
20%
Relapsed or Refractory Diffuse Large B-cell Lymphoma
20%
Alemtuzumab
20%
Peripheral T-cell Lymphoma
20%
Thymus
20%
Activation-regulated Chemokine
20%
Waldenström Macroglobulinemia
20%
Acute Myeloid Leukemia
20%
Human Leukocyte Antigen
20%
Disease-free Survival
20%
Event-free Survival
20%
Lymphoma
20%
Rituximab
20%
Confidence Interval
17%
Chemotherapy
17%
Phase II Trial
17%
Marrow
15%
CHOP Therapy
15%
Fast Response
15%
Chemoradiotherapy
15%
Treatment Response
14%
Diffuse Large B-cell Lymphoma (DLBCL)
13%
Hematopoietic Stem Cell Transplantation
13%
Sequential Therapy
13%
Working Party
13%
Clinical Presentation
13%
Epstein-Barr Virus DNA Load
12%
R-CHOP
11%
Cyclophosphamide
11%
F-18 Fluorodeoxyglucose Positron Emission Tomography
11%
Doxorubicin
11%
Reduced-intensity Conditioning
11%
Allograft
11%